



*EHME and JPS contributed equally to the
manuscript.
Parts of this paper have been presented as a
poster at the meeting of the Schizophrenia
International Research Society (SIRS) in
Florence, Italy, 4–8 April 2018.
Cite this article: Weijers J, Ten Kate C,
Viechtbauer W, Rampaart LJA, Eurelings EHM,
Selten JP (2020). Mentalization-based
treatment for psychotic disorder: a rater-
blinded, multi-center, randomized controlled
trial. Psychological Medicine 1–10. https://
doi.org/10.1017/S0033291720001506
Received: 3 December 2019
Revised: 29 April 2020
Accepted: 6 May 2020
Key words:
Mentalization-based treatment; psychosis;
randomized controlled trial; schizophrenia;
social functioning
Author for correspondence:
J. Weijers, E-mail: j.weijers@rivierduinen.nl
© The Author(s), 2020. Published by
Cambridge University Press. This is an Open
Access article, distributed under the terms of
the Creative Commons Attribution licence
(http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted re-use,
distribution, and reproduction in any medium,
provided the original work is properly cited.
Mentalization-based treatment for psychotic
disorder: a rater-blinded, multi-center,
randomized controlled trial
J. Weijers1,2 , C. Ten Kate1, W. Viechtbauer2, L. J. A. Rampaart1,
E. H. M. Eurelings3,* and J. P. Selten1,2,*
1Rivierduinen Institute for Mental Health Care, Sandifortdreef 19, 2333 ZZ Leiden, The Netherlands; 2Department
of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University,
Universiteitssingel 50, 6229 ER Maastricht, The Netherlands and 3Department of Clinical Psychology, Health, and
Neuropsychology, Leiden University, Wassenaarseweg 52, 2333 AK Leiden, The Netherlands
Abstract
Background. Impaired mentalizing ability – an impaired ability to understand one’s own and
other people’s behavior in terms of mental states – is associated with social dysfunction in
non-affective psychotic disorder (NAPD). We tested whether adding mentalization-based
treatment for psychotic disorder (MBTp) to treatment as usual (TAU) results in greater
improvement in social functioning.
Methods. Multicenter, rater-blinded, randomized controlled trial. Eighty-four patients with
NAPD were assigned to TAU or MBTp plus TAU. Patients in the MBTp group received
18 months of MBTp, consisting of weekly group sessions and one individual session per 2
weeks. Social functioning was measured using the Social Functioning Scale. We conducted
ANCOVAs to examine the difference between treatment conditions directly after treatment
and at 6-month follow-up and performed moderation and mediation analyses.
Results. Intention-to-treat analyses showed no significant differences between groups
post-treatment ( p = 0.31) but revealed the MBTp group to be superior to TAU at follow-
up ( p = 0.03). Patients in the MBTp group also seemed to perform better on measures of
mentalizing ability, although evidence of a mediation effect was limited ( p = 0.06). Lastly,
MBTp treatment was less effective in chronic patients than in recent-onset patients
( p = 0.049) and overall symptoms at baseline were mild, which may have reduced the overall
effectiveness of the intervention.
Conclusion. The results suggest that MBTp plus TAU may lead to more robust improvements
in social functioning compared to TAU, especially for patients with a recent onset of
psychosis.
Introduction
Non-affective psychotic disorder (NAPD) is often accompanied by a significant reduction in
social functioning, the causes of which are still poorly understood. Impaired mentalizing,
defined as the imaginative mental activity that lets us perceive and interpret human behavior
in terms of intentional mental states (Bateman & Fonagy, 2004), is a potential candidate.
Deficits in several dimensions of mentalizing have been widely observed in NAPD, such as
an impaired ability to infer others’ mental states, i.e. ‘Theory of Mind’ (Bechi et al., 2019;
Sprong, Schothorst, Vos, Hox, & Van Engeland, 2007), and to identify and describe one’s
own and others’ emotional states (Kohler, Walker, Martin, Healy, & Moberg, 2010;
O’Driscoll, Laing, & Mason, 2014; Trémeau, 2006). Next to mentalizing impairments (see
Fett, Viechtbauer, Penn, van Os, & Krabbendam, 2011 for an overview), impaired metacogni-
tion, a construct largely overlapping with mentalization, has also been identified as a major
contributor to social dysfunction (e.g. see Arnon-Ribenfeld, Hasson-Ohayon, Lavidor,
Atzil-Slonim, & Lysaker, 2017 for an overview; Gagen, Zalzala, Hochheiser, Martin, &
Lysaker, 2019; Bröcker et al., 2020), particularly deficits in specific sub-components of meta-
cognition such as empathic perspective taking and self-reflectivity (see Brüne, Dimaggio, and
Lysaker, 2011 for a review).
Mentalization-based treatment (MBT) is an evidence-based treatment for borderline per-
sonality disorder (BPD) (Bateman & Fonagy, 1999), associated with a long-lasting decrease
of depressive symptoms, suicidal and para-suicidal behavior, number of days hospitalized,
and improvements in social and interpersonal functioning. Interestingly, Bateman and
Fonagy (2001, 2008) found that treatment effects had further increased both at 18 months
and 5 years after treatment termination. Later studies also revealed that MBT can improve
mentalizing (de Meulemeester, Van Steelandt, Luyten, & Lowyck, 2018; Rossouw & Fonagy,
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2012). This has sparked interest in MBT as a treatment for NAPD
(Brent & Fonagy, 2014; Weijers et al. 2016; Weijers et al., 2020)
and its prodromal states (Debbané et al., 2016).
The current study is a randomized controlled trial examining
whether patients who receive mentalization-based treatment for
psychotic disorder (MBTp) show a greater improvement in social
functioning than patients who receive treatment as usual (TAU)
only. If so, we hypothesized that the effect of MBTp on social
functioning was at least partially mediated by mentalizing ability.
Additionally, patients who receive MBTp were expected to fare
better on the following outcomes: quality of life; positive, negative,
anxious, and depressive symptoms; insight; drug use; psychotic
experiences; negative and positive affect; social stress; and social
stress reactivity (i.e. the affective and psychotic reaction to social
stress).
Methods
A protocol for this study was registered prior to the implementa-
tion of the study (Dutch Trial Register: Trial NL4588), approved
by the Medical Ethics Committee of Maastricht University and
published. The present paper provides essential information
only. See the online Supplementary material and Weijers et al.
(2016) for more details.
Participants
Clinicians of community treatment teams at two mental health
care facilities in the Netherlands (GGZ Rivierduinen and
Altrecht) scanned their caseloads for patients eligible to partici-
pate. Inclusion criteria were: at least 6 months, but no more
than 10 years of treatment for NAPD; between 18 and 55 years
of age. Exclusion criteria were: intellectual disability and/or illiter-
acy; insufficient knowledge of the Dutch language; addiction to
such an extent that it necessitated inpatient detoxification.
Therapy
Treatment as usual
Patients received treatment according to the Dutch multi-
disciplinary guideline for schizophrenia (van Alphen et al.,
2012) and according to the so-called ‘Functional Assertive
Community Treatment’ (FACT) model. FACT teams consist of
nurses, psychologists, and psychiatrists.
MBTp
MBT consists of individual and group psychotherapy. MBT aims
to improve mentalizing capacity, especially under stressful condi-
tions and, by doing so, is expected to reduce psychopathology and
improve functioning (Fonagy & Bateman, 2006). The current
study used the original treatment manual for BPD, with therapists
focusing on affect, the establishment of a secure treatment rela-
tionship, balancing the complexity of mentalization interventions
and stress, and adopting a ‘not-knowing’ therapeutic stance. The
length of therapy – 18 months – remained unchanged, but the
intensity of the original program was significantly reduced to a
1 h group session per week and a half-hour individual session
once per 2 weeks. At the start of treatment, around four sessions
were provided to educate patients about key aspects of mentaliz-
ing. The individual therapy sessions provided the opportunity to
explore difficulties encountered during group sessions or in daily
life based on five global areas: commitment to treatment,
psychiatric symptoms, social interaction, destructive/avoidant
behavior, and community functioning.
Assessment
All outcomes mentioned below were obtained at three points in
time: at baseline (T0), after 18 months, immediately post-
treatment (T2), and at a 6-month follow-up (T3). Only the
Experience Sampling Method (ESM) questionnaires (see below)
were filled out at 9 months (T1).
Diagnosis
Table 1 shows the DSM-IV-TR diagnoses (APA, 2000) established
by psychiatrists prior to participation. The researchers assessed all
patients before participation using the Comprehensive
Assessment of Symptoms and History (CASH; Andreasen et al.,
1992), a diagnostic interview. Participants who had been given a
diagnosis in the NAPD spectrum also had NAPD according to
information derived from the CASH, although specific DSM-IV
diagnoses could differ between clinicians and researchers, with
an acceptable rate of agreement (Cohen’s κ = 0.6).
Primary outcome
Social functioning. Social functioning was measured using the
Social Functioning Scale (SFS; Birchwood, Smith, Cochrane,
Wetton, & Copestake, 1990), an observer-rated interview that
measures seven dimensions of social functioning: social engage-
ment, interpersonal behavior/communication, independence-
competence, independence-performance, recreational activities,
pro-social activities, and employment/occupation. Subscale scores
were averaged to create an overall social functioning score, with
higher scores representing higher social functioning (possible
range: 59.7–134.9). The SFS is often referred to as ‘behaviorally
anchored’ because it uses concrete examples to rate social func-
tioning (e.g. the amount of friends or time spent alone) avoiding
the need for normative judgment and evaluative decisions. The
scale has been found to be reliable, responsive to change, and
to have a good construct validity (Birchwood et al., 1990).
Secondary outcomes
Mentalizing ability was assessed with the Thematic Apperception
Test (TAT; Murray, 1938) and scored with the Social Cognition
and Object Relations System (SCORS; Westen, 1991). Four
dimensions of social cognition were scored: complexity of repre-
sentations of people (i.e. the ability to distinguish between one’s
own and another’s perspective), understanding of social causality
(i.e. the ability to construct a logical and psychologically minded
explanation of others’ behavior), affect tone of relationships (i.e.
the degree to which social interaction is viewed to be basically
benign or malevolent), and capacity for emotional investment
(i.e. the degree to which moral standards have been developed
and others are treated as ends rather than means). Each dimen-
sion is scored on a five-point scale, with higher scores represent-
ing higher mentalizing ability.
Theory of mind was assessed using the Hinting Task
(Corcoran, Mercer, & Frith, 1995), scored on a 20-point scale,
with higher scores representing a better theory of mind.
Positive symptoms/Negative symptoms/Depression/Anxiety/
Lack of insight were measured using the Dutch translation
(Wolthaus et al., 2000) of the Positive and Negative Syndrome
Scale (PANSS; Kay, Fiszbein, & Opler, 1987) on seven-point
2 J. Weijers et al.
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Likert scales. Subscales p and N each comprised the average of
seven items (see Weijers et al., 2016 for more details).
Quality of life was measured with the Manchester Short
Assessment of Quality of Life (Priebe, Huxley, Knight, & Evans,
1999).
Experience sampling variables. Participants received a digital
diary – the ‘PsyMate’ – to facilitate the sampling of experiences
in daily life, i.e. the ESM. At T0, T1, T2, and T3, for 6 days,
the Psymate beeped 10 times a day at irregular intervals to prompt
participants to fill out digital questionnaires. At each beep,
patients rated how much positive affect (an average score of
‘happy’, ‘satisfied’, ‘cheerful’, ‘relaxed’, and ‘enthusiastic’), negative
affect (‘anxious’, ‘lonely’, ‘insecure’, ‘irritated’, ‘down’, ‘guilty’, and
‘gloomy’), psychotic symptoms (‘I feel suspicious’, ‘I am afraid of
losing control’, ‘I feel that others don’t like me’, ‘I feel that others
want to hurt me’, ‘My thoughts are influenced by other people’, ‘I
feel unreal’, and ‘I hear voices’), and social stress [‘I would rather
be alone’ and ‘I like the present company’ (reverse coded)] they
experienced. All items were rated on seven-point Likert scales.
In order to measure drug use, at each beep, patients were asked
whether they had used cannabis or other drugs since the last
beep, coded 0 or 1 (for any drug use).
Moderators
Personality organization and somatization of psychopathology.
Assessment of personality organization (PO) and the tendency
to somatize severe psychopathology was measured using theory-
driven analysis (Eurelings-Bontekoe, Peen, Noteboom, Alkema,
& Dekker, 2012) of the results on the Dutch short Form of the
MMPI (DSFM; Luteijn & Kok, 1985). Four levels of PO are dis-
tinguished: neurotic, borderline, narcissistic, and psychotic.
The DSFM Somatization subscale measures the ability to be
aware of and to report bodily sensations, while the
Psychopathology subscale measures the degree of severe psycho-
pathology. Favorable affect regulation through somatization will
be expressed as the relative position of scores on the subscale
somatization to that on the psychopathology subscale
(Eurelings-Bontekoe & Koelen, 2007).
Childhood trauma. The Childhood Experience of Care and
Abuse (CECA; Bifulco, Brown, & Harris, 1994) is a semi-
structured interview that aims to assess details and the time-
sequence of traumatic childhood experiences. It assesses lack of
care (neglect, antipathy), physical abuse, sexual abuse, and psy-
chological abuse.
Adherence to pharmacological treatment. Adherence to the
prescribed medication was measured with the Medication
Adherence Questionnaire (MAQ; Morisky, Green, & Levine,
1986).
Duration of illness. This was defined and measured based on
the number of years since the onset of the first psychotic episode.
Statistical analyses
Main analyses
First, repeated-measures analyses on the basis of the
intention-to-treat principle – with social functioning at T0 and
either T2 or T3 – were used to determine change over time in
social functioning for both the TAU and MBTp groups. Second,
for all primary and secondary outcomes, ANCOVAs – with
treatment condition as a between-subjects variable, and the
performance on the variables at either T2 or T3 as dependent
variables – were used to examine the difference on secondary out-
comes, adjusted for baseline levels. According to the European
Table 1. Demographics and clinical characteristics of patients at baseline participating in a randomized trial to test the effectiveness of mentalization-based
treatment for psychotic disorder
Variable TAU, mean (S.D.) N MBT-P, mean (S.D.) N p*
Age in years 31.88 (9.43) 42 31.21 (7.80) 42 0.73
Age of onset 26.71 (9.11) 42 25.76 (7.51) 42 0.60
Duration of illness 5.17 (3.32) 42 5.45 (3.54) 42 0.70
Gender 0.12
Male, # 30 23
Female, # 12 19
Diagnosis (DSM-IV-TR) 0.76
Schizophrenia 28 26
Schizoaffective disorder 4 7
Psychotic disorder N.O.S. 6 7
Brief psychotic disorder 2 2






*Based on independent samples t tests for continuous variables and χ2 tests for categorical ones.
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Medicines Agency guidelines (2017), dividing outcomes into pri-
mary and secondary outcomes is a way to control the Type I error
rate. However, in this way, secondary outcomes can only be con-
sidered as indications – not evidence – of potential treatment
effects.
Handling of missing data. The analyses of the primary and sec-
ondary outcomes were carried out with imputed data, allowing for
the use of a proper ‘intention-to-treat’ analysis. Missing data were
handled by multiple imputation (Schafer, 1999) using independ-
ent variables that were likely to predict drop-out: a lack of insight,
positive symptoms, age, gender, a history of drug abuse,
unemployment, treatment allocation, and poor social functioning
at T0 (see Nosé, Barbui, Gray, & Tansella, 2003 for an overview).
For each analysis, five imputed datasets were created using a fully
conditional Markov chain Monte Carlo (MCMC) approach.
Results from analyses conducted with the imputed datasets were
combined using Rubin’s rules.
Mediation analyses
To test whether the effect of treatment condition on social func-
tioning was mediated by mentalizing ability, we conducted medi-
ation analyses with any of the scales of the SCORS or the hinting
task as mediators, provided they were significantly affected by
treatment condition. SPSS version 22 combined with Hayes’s
PROCESS macro (Preacher & Hayes, 2004) was used for the
mediation analyses. The process macro uses non-parametric boot-
strapping, which involves random resampling of observations
with replacement to obtain confidence intervals for the indirect
effect (and functions thereof). The bootstrap confidence intervals
were based on 5000 resamples. Mediation effects are considered
significant if the confidence interval does not contain 0. All medi-
ation analyses included treatment condition as an independent
variable, social functioning at either T2 or T3 as dependent vari-
ables, mentalization at T2 or T3 as a mediator, and baseline social
functioning as a covariate.
Moderation analyses
As described in Weijers et al. (2016), we also sought to examine
potential modifiers of the treatment effect, including severity of
childhood trauma, type of PO, the degree of somatization of psy-
chopathology, adherence to pharmacological treatment, total
number of hours of attended MBTp sessions, and duration of ill-
ness. Moderation analyses included treatment condition as an
independent variable, the moderator and its interaction with
treatment condition as independent variables, social functioning
at T0 as a covariate, and social functioning at T2 or T3 as a
dependent variable. Since PO is a categorical variable, it was
dummy-coded creating four new dichotomous variables (for
neurotic, borderline, psychotic, and narcissistic PO).
Additionally, since social functioning deteriorates most in the
first 5 years after the onset of illness (Birchwood & Macmillan,
1993) and the first 5 years of NAPD are considered a crucial per-
iod for intervention (Birchwood & Macmillan, 1993; McGorry,
Nelson, Goldstone, & Yung, 2010), duration of illness was dichot-
omized (⩽5 years or >5 years). Somatization of psychopathology
is a dichotomous score representing an either favorable (relatively
high degree of somatization with high psychopathology) or
unfavorable personality characteristic (relatively low somatization
with high degree of psychopathology).
Multilevel analyses
The hierarchically structured measurements collected with ESM
necessitate a multilevel analysis, because there are multiple mea-
surements per day, for up to 6 days for each patient. In particular,
for each subject, up to 60 measurements were available for each
outcome of interest at each time point and hence up to 240 mea-
surements overall. All available measurements were included in
these analyses. However, as in previous ESM studies (e.g.
Snippe et al., 2017), participants were included in these analyses
only if they had filled out at least 20 questionnaires at baseline.
We used the same criterion for follow-up measurements.
Differences in changes between treatment conditions over time
(i.e. across the different measurement periods) regarding social
stress, psychotic experiences, negative affect, and positive affect
were analyzed using mixed-effects regression models.
Differences in changes between treatment conditions over time
regarding illicit drug use were analyzed using a binomial logistic
mixed-effects regression model. The models included treatment
condition, time (coded as 0 to 3 for T0 through T3, respectively),
and their interaction term as predictors, with either psychotic
experiences, social stress, negative affect, positive affect, or drug
use as dependent variables and random intercepts and random
slopes for time at the subject level. Interest was focused on the
condition × time interaction (i.e. Did the outcome of interest
change differentially for the two groups over the course of the
four measurement occasions?).
Reactivity to social stress was conceptualized as the association
between social stress (predictor) and negative affect, positive
affect, or psychotic experiences (outcomes). Analyses of treatment
effect on stress reactivity included treatment condition, time,
social stress, and their two- and three-way interaction terms as
predictors, with either psychotic experiences, negative affect, or
positive affect as dependent variables. These models included ran-
dom intercepts and random slopes for time and social stress at the
subject level. Here, we were specifically interested in the three-way
interaction (i.e. Did the association between an outcome of inter-
est and social stress change differentially for the two groups over
the course of the four measurement occasions?).
Results
Demographics and patient characteristics
Written informed consent was obtained from 90 participants.
Two participants failed to complete the baseline measurement,
one patient dropped out before randomization and did not
want his data stored. Three other patients were excluded during
the trial: two participants were diagnosed with substance use dis-
orders during the trial and were unwilling to enter inpatient
detoxification programs, and one patient turned out to be too
old (57 years). They were excluded from the study.
Consequently, intention-to-treat analyses were conducted with
84 patients.
There were no significant differences between groups on any of
the demographic variables or baseline measurements, except for
anxiety and depression ( p = 0.049 for both), which were higher
in the MBTp group (see Table 2). In the MBTp group, a total
of 21 patients had received cognitive behavioral therapy (CBT)
at some point before the trial, opposed to 23 patients in the
TAU group. One patient in the MBTp group received CBT during
the trial, as opposed to seven participants in the TAU group.
There were no significant differences between groups in
4 J. Weijers et al.
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Table 2. Results of the intention-to-treat ANCOVAsa comparing the effectiveness of mentalization-based treatment for psychotic disorder (MBT-p) with treatment as
usual (TAU)
Outcome variable TAU N MBT-p N F ηp
2 p
Social functioning
Baseline (T0) 110.01 (7.09) 42 108.41 (7.94) 42 0.96 0.01 0.33
Post-treatment (T2) 112.10 (7.34) 42 112.54 (7.28) 42 1.01 0.03 0.31
Follow-up (T3) 111.44 (6.97) 42 113.95 (6.86) 42 2.17 0.06 0.03
Positive symptoms
Baseline (T0) 10.86 (4.36) 42 12.26 (4.39) 42 2.17 0.03 0.14
Post-treatment (T2) 11.23 (4.56) 42 11.20 (3.90) 42 1.40 0.02 0.29
Follow-up (T3) 11.73 (4.41) 42 10.94 (3.55) 42 4.61 0.05 0.07
Negative symptoms
Baseline (T0) 11.67 (5.24) 42 12.45 (6.13) 42 0.40 0.005 0.53
Post-treatment (T2) 11.55 (4.11) 42 11.40 (4.87) 42 0.30 0.004 0.69
Follow-up (T3) 11.29 (3.70) 42 10.97 (4.97) 42 0.41 0.005 0.60
Anxiety
Baseline (T0) 2.00 (1.21) 42 2.60 (1.50) 42 4.01 0.05 0.049
Post-treatment (T2) 2.45 (1.24) 42 2.88 (1.31) 42 1.88 0.02 0.50
Follow-up (T3) 2.43 (1.25) 42 2.27 (1.07) 42 1.13 0.01 0.41
Depression
Baseline (T0) 1.90 (1.34) 42 2.50 (1.31) 42 4.23 0.05 0.049
Post-treatment (T2) 1.87 (1.10) 42 2.43 (1.31) 42 1.84 0.02 0.19
Follow-up (T3) 2.06 (1.29) 42 1.99 (1.16) 42 0.91 0.01 0.39
Lack of insight
Baseline (T0) 1.62 (1.27) 42 1.67 (1.14) 42 0.03 >0.001 0.86
Post-treatment (T2) 1.91 (1.20) 42 1.41 (0.71) 42 6.62 0.08 0.03
Follow-up (T3) 1.91 (0.94) 42 1.50 (1.10) 42 5.32 0.06 0.03
Theory of mind
Baseline (T0) 16.50 (2.67) 42 17.52 (2.42) 42 3.39 0.40 0.07
Post-treatment (T2) 17.78 (1.78) 42 18.87 (1.30) 42 7.49 0.08 0.02
Follow-up (T3) 17.70 (2.09) 42 18.90 (1.52) 42 7.38 0.08 0.02
Complexity
Baseline (T0) 11.74 (1.61) 42 12.19 (1.15) 42 2.19 0.03 0.14
Post-treatment (T2) 11.61 (0.92) 42 11.99 (1.03) 42 2.90 0.03 0.14
Follow-up (T3) 11.47 (0.97) 42 12.25 (1.40) 42 9.16 0.10 0.03
Understanding social causality
Baseline (T0) 11.57 (2.00) 42 12.12 (2.23) 42 1.40 0.02 0.24
Post-treatment (T2) 10.36 (1.82) 42 11.68 (1.85) 42 10.00 0.11 0.006
Follow-up (T3) 10.66 (1.86) 42 12.71 (2.44) 42 17.85 0.18 >0.001
Affect-tone
Baseline (T0) 18.60 (2.13) 42 18.00 (2.44) 42 1.42 0.02 0.24
Post-treatment (T2) 18.73 (2.79) 42 18.88 (3.58) 42 0.87 0.01 0.58
Follow-up (T3) 19.38 (2.55) 42 20.15 (2.94) 42 2.43 0.03 0.14
Emotional investment
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antipsychotic medication adherence (all p’s > 0.31), type (all p’s >
0.27), or dosage (all p’s > 0.25) at either T0, T2, or T3.
Drop-out and non-compliance
See Fig. 1. Patients in the MBTp condition followed an average of
29.9 group sessions (range: 0–68) and an average of 8.6 h of indi-
vidual therapy (range: 0–20).
Safety
Following the regulations of the Medical-Ethics Committee of
Maastricht University, serious adverse events such as hospitaliza-
tion were registered. Among those patients allocated to MBTp, six
patients were hospitalized due to exacerbations of symptoms. Of
those, only one was actively following MBTp at the time of hos-




Repeated-measures analyses on the basis of the intention-to-treat
principle with imputed data revealed that patients in both the
MBTp group [F(1,41) = 21.52, ηp
2 = 0.34, ppooled < 0.001] and in
the TAU group showed significant improvements in social func-
tioning at T2 [F(1,41) = 7.47, ηp
2 = 0.15, ppooled = 0.01]. Based on
the benchmarks established by Cohen (1988; 0.01 = small; 0.06
= moderate, 0.14 = large), these effects can be considered large.
At T3, however, the effect in the TAU group was no longer signifi-
cant [F(1,41) = 2.25, ηp
2 = 0.05, ppooled = 0.14], while the MBTp
group continued to show a large effect [F(1,41) = 20.99, ηp
2 = 0.34,
ppooled < 0.001]. ANCOVAs on the basis of the intention-to-treat
principle with imputed data revealed that the improvement in
the MBTp group was not significantly greater than in the TAU
group at T2 [t(80) = 1.01, ηp
2
ooled = 0.03, ppooled = 0.32], but was
significantly greater at T3 [t(80) = 2.17, ηp
2
ooled = 0.06, ppooled =
0.03].
Secondary outcomes
Please see Table 2 for treatment effects on the secondary outcome
variables.
Mediation analyses
Only regarding the follow-up measurement (T3) did treatment
condition have a significant effect on social functioning.
Additionally, treatment condition only had a significant effect
on understanding of social causality and on theory of mind.
Mediation analyses were therefore only conducted for these two
mediators and only at T3. Bootstrapped mediation analyses in
turn revealed that social functioning at T3 was significantly pre-
dicted by theory of mind (b = 0.79, ppooled = 0.04), but not by
understanding of social causality (b = 0.39, ppooled = 0.25). Lastly,
while accounting for theory of mind, the effect of treatment con-
dition on social functioning became insignificant (b = 1.51,
ppooled = .27), suggesting the presence of mediation. However,
the confidence interval of the mediation effect contained 0
(95% CI −0.002 to 0.33).
Moderation analyses
Moderation analyses did not reveal moderation effects of medica-
tion adherence, total hours of MBTp attendance, PO, somatiza-
tion, or childhood trauma on treatment effect at T2 or T3 (all
p’s > 0.07). However, duration of illness significantly moderated
the treatment effect on social functioning at T3 [ΔF(1,58) = 4.05,
p = 0.049, ΔR2 = 0.05], but not at T2 ( p = 0.38). Relatively
recent-onset patients (⩽5 years) in the MBTp group showed sig-
nificantly higher levels of social functioning [F(1,33) = 10.50, ηp
2 =
0.17, p = 0.02] at T3 (M = 116.58, S.D. = 7.17) than the more
chronic patients (>5 years) in the MBTp condition (M = 109.95,
S.D. = 6.04) and the relatively recent-onset patients in the TAU
group [M = 111.40, S.D. = 6.71; F(1,34) = 6.48, ηp
2 = 0.17, p = 0.02].
Multilevel analysis
For social stress, treatment condition interacted significantly with
the time variable, with patients in the MBTp condition showing a
greater decrease in reported social stress over the course of four
time points (b = −0.32, 95% CI −0.58 to −0.059, p = 0.02).
Further analyses showed no significant differences in change
over time on psychotic experiences, negative affect, positive affect,
or illicit drug use between treatment conditions (all p’s > 0.06).
The interaction term of treatment condition, time, and social
stress was not a significant predictor for psychotic experiences,
negative affect, or positive affect (all p’s > 0.12), meaning that
there were no differences in how social stress reactivity changed
over time between the two treatment conditions.
Discussion
Main findings
The current trial tested whether adding MBTp to TAU resulted in
greater improvement in social functioning than TAU alone.
Intention-to-treat analyses revealed that patients in both the TAU
and MBTp conditions showed large, significant improvements
Table 2. (Continued.)
Outcome variable TAU N MBT-p N F ηp
2 p
Post-treatment (T2) 8.72 (2.85) 42 9.42 (3.05) 42 2.30 0.03 0.29
Follow-up (T3) 8.63 (2.01) 42 9.50 (2.24) 42 3.95 0.05 0.06
Quality of life
Baseline (T0) 3.51 (0.59) 42 3.59 (0.56) 42 0.46 0.006 0.50
Post-treatment (T2) 3.78 (0.62) 42 3.69 (0.56) 42 0.35 0.019 0.37
Follow-up (T3) 3.80 (0.48) 42 3.84 (0.54) 42 0.20 >0.001 0.55
aPost-treatment and follow-up analyses were adjusted for baseline performance.
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on social functioning post-treatment. There was no significant dif-
ference between MBTp and TAU at this point in time. However,
the improvements were more robust in the MBTp group and super-
ior to TAU, remaining significant at a 6-month follow-up.
Additionally, evidence suggests that duration of illness moderated
the treatment effect at follow-up, implying that results may be espe-
cially robust in patients with a relatively recent onset of illness.
Interpretation and comparison to previous findings
It may not come as a surprise that patients who received TAU,
provided according to the FACT model, showed improvement
in social functioning post-treatment, since FACT teams include
several professionals specialized in helping patients to structure
their social lives. This also corroborates earlier findings
(Drukker, Visser, Sytema, & Van Os, 2013). The addition of indi-
vidual placement and support – an evidence-based intervention
that consists of targeted support in employment or education –
may have further contributed to social functioning (Hoffmann,
Jäckel, Glauser, & Kupper, 2012; Pos et al., 2019). Still, functional
recovery appeared to be more robust in the MBTp group, which
may be attributed to the ‘sleeper effect’ observed in previous
studies concerning the long-term effects of MBT. Bateman and
Fonagy (2001) argued that improved mentalizing enabled
patients to better cope with the stresses of everyday life in the
long run.
Fig. 1. CONSORT 2010 flow diagram.
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However, the lack of difference between the conditions post-
treatment and the significant difference at follow-up may also
have different origins. First, more patients in the TAU group
(n = 7) received CBT between the pre- and post-treatment meas-
urement as opposed to the MBTp group (n = 1). None received
CBT in the follow-up period. As CBT has been shown to produce
a significant but non-robust effect on social functioning (Laws
et al., 2018), CBT may therefore have made a contribution to
the overall gain in social functioning in the TAU group between
pre- and post-treatment which did not last after 6 months.
Second, more participants in the TAU group (n = 5) than in the
MBTp group (n = 0) discontinued FACT during the follow-up
period which may have further reduced functional gains at
follow-up.
Interestingly, while the evidence for MBT’s proposed mechan-
ism of change – the improvement of mentalizing ability – is still
scarce (Rossouw & Fonagy, 2012), the current results suggest that
patients in the MBTp group did perform better on several mea-
sures of mentalizing ability, including theory of mind, under-
standing of social causality, and complexity of representations.
They also showed an increase in insight. However, mediation ana-
lyses offered only limited evidence that an improvement of men-
talization drove this treatment effect.
Furthermore, no treatment effects were observed on the clin-
ical symptoms of NAPD. Comparison to previous studies revealed
that our sample suffered from relatively mild symptoms, which
may account for the lack of observed treatment effects. Scores
for clinical symptoms at baseline were similar to those for remit-
ted patients (Češková, Přikryl, Kašpárek, & Ondrušová, 2005;
Phahladira et al., 2018). These baseline scores likely reflect a
recruitment bias. During the selection procedure, treatment staff
members were asked to scan their caseloads for patients who
were eligible for participation. Given that only about 20% of avail-
able patients were referred to the intake of the trial, it is possible
that staff members approached the more stable patients.
Additionally, the observed effects of MBTp on social function-
ing appear to be greatest in the subgroup of relatively recent-onset
patients. Recent patients in the MBTp group showed relatively
large improvements, achieving levels of functioning (M =
116.58) that are between those of NAPD patients (M = 108.07)
and healthy controls (M = 123.36), as established by Addington
and Addington (2008). These results are in line with a growing
body of literature suggesting that duration of illness is a predictor
of poor treatment response (Lieberman, Dixon, & Goldman,
2013; Lincoln et al., 2014) and that the first 5 years of NAPD con-
stitute a crucial period for intervention (Birchwood & Macmillan,
1993; McGorry et al., 2010). NAPD tends to involve a multitude
of problems that may complicate therapy as the disorder pro-
gresses, including cognitive decline (Wykes, Huddy, Cellard,
McGurk, & Czobor, 2011) and greater difficulty challenging
long held beliefs (Lincoln et al., 2014). Consequently, the choice
to include patients that had received treatment for up to 10
years before enrollment in the current study may have limited
the overall effect of MBTp, which may be most effectively imple-
mented in the early stages of the disorder (Debbané et al., 2016).
Strength and limitations
The current study used a rigorous research design: randomization,
taking into account baseline performance and the use of blinded
raters. Additionally, it is the first study to examine the effective-
ness of MBT in NAPD and it is one of the few studies to examine
whether MBT improves mentalizing ability (see Rossouw &
Fonagy, 2012, for another example). Lastly, intensive supervision
was provided to ensure that professionals adhered to the MBT
model.
Naturally, several limitations apply. First, the two treatment
conditions cannot be deemed equal, making it difficult to deter-
mine whether observed differences were actually caused by the
interventions themselves. Participants in the MBTp group
received group therapy. On the other hand, participants in the
TAU group received more CBT between the baseline and post-
treatment measurements. Second, with a drop-out rate of around
20%, the results of our study should be treated with caution.
Third, the moderation analyses were likely underpowered.
Fourth, except for the ‘complexity of representations’ dimension,
we chiefly measured other-oriented, cognitive forms of mentaliz-
ing. Fifth, we are precluded from drawing conclusions about the
secondary outcomes. These should be treated as indications of
treatment effect. Sixth, many patients found it difficult to attend
weekly sessions. This may have reduced the effectiveness of the
intervention. Consequently, we think that future efforts should
not be aimed at increasing the frequency of sessions, but perhaps
at lengthening the duration of the treatment period, as some
patients were disappointed that they had to stop after 18 months.
Seventh, the Hinting Task has been criticized for a ceiling effect,
especially in high functioning patients (e.g. Roberts & Penn,
2009), meaning that the pertinent results should be interpreted
with caution.
Conclusion
The results of this study suggest that MBTp may lead to more
robust changes in social functioning than TAU alone.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291720001506.
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